Together, these findings demonstrate the importance of tumor-specific genetic alterations as a mechanism for reprogramming the immune landscape in cancer and highlight p-VHL loss–mediated CX3CL1 upregulation as a specific driver of myeloid inflammation in ccRCC. The gene discussed is CX3CL1; the disease is nonpapillary renal cell carcinoma.